Capsules

Sutent Capsules

Product Details:
  • Category: Breast Cancer, Lung Cancer, Blood Cancer, Stomach Cancer
  • Dosage Form: Inhalation, Parenteral
  • Dose Strength (Mg): 12.5 mg
  • Form: Capsules
  • Packaging Size: 1 strip 7 capsules
  • Packaging Type: Sachet
  • Type: Allopathic

PFIZER
"SUTENT, an oral multi-kinase inhibitor, is the malate salt of sunitinib. Sunitinib malate is described chemically as Butanedioic acid, hydroxy-, (2S)-, compound with N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro- 1,2-dihydro-2-oxo-3H-indol-3-ylidine)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide (1:1). The molecular formula is C22H27FN4O2 • C4H6O5 and the molecular weight is 532.6 Daltons. The chemical structure of sunitinib malate is: SUTENT® (sunitinib malate) Structural Formula Illustration Sunitinib malate is a yellow to orange powder with a pKa of 8.95. The solubility of sunitinib malate in aqueous media over the range pH 1.2 to pH 6.8 is in excess of 25 mg/mL. The log of the distribution coefficient (octanol/water) at pH 7 is 5.2. SUTENT (sunitinib malate) capsules are supplied as printed hard shell capsules containing sunitinib malate equivalent to 12.5 mg, 25 mg or 50 mg of sunitinib together with mannitol, croscarmellose sodium, povidone (K-25) and magnesium stearate as inactive ingredients.
The orange gelatin capsule shells contain titanium dioxide, and red iron oxide. The caramel gelatin capsule shells contain titanium dioxide, red iron oxide, yellow iron oxide and black iron oxide. The white printing ink contains shellac, propylene glycol, sodium hydroxide, povidone and titanium dioxide."
ONCOLOGY
Looking for Capsules ?
Share Us:
© CSC Pharmaceuticals International
Desktop Site Back to top